According to stock data, at the beginning of 2020, Pfizer, Johnson &amp; Johnson, AstraZeneca, Moderna, Biontech and Novavax, had a market value of about $697,000; by the end of 2021 they were worth more than $1 trillion, which represents an increase of 50%